Diffuse large B-cell lymphoma – a new look and old prognostic factors
Camelia Dobrea, Hamed Al Salamat, Anca Roxana Lupu
Abstract: Diffuse large B-cell lymphoma (DLBCL) accounts for about 30% of non-Hodgkin’s lymphoma (NHL) cases. The 2008 WHO Classification of Lymphoid Neoplasms recognizes several clinicopathological variants, subtypes and distinct disease entities of DLBCL. We present a review of clinical, pathological and molecular factors with implication in DLBCL behavior. Even if the golden standard therapy for CD20-positive DLBCL is still represented by R-CHOP, prognostic factor assessment could open new therapeutic perspectives.
Keywords: diffuse large B cell lymphoma,prognostic factors
|